• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Veradigm Inc. filed SEC Form 8-K: Leadership Update

    3/18/25 5:17:28 PM ET
    $MDRX
    EDP Services
    Technology
    Get the next $MDRX alert in real time by email
    8-K
    NONE false 0001124804 0001124804 2025-03-18 2025-03-18

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 18, 2025

     

     

    VERADIGM INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   000-32085   36-4392754
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    222 Merchandise Mart

    Chicago, Illinois

      60654
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 800 334-8534

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, par value $0.01 per share   MDRX   N/A (OTC Expert Market)

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 1.01.

    Entry into a Material Definitive Agreement.

    Registration Rights Agreement

    In connection with the appointment of Mr. Jonathan Sacks to the board of directors (the “Board”) of Veradigm Inc. (the “Company”) as described in Item 5.02 of this Current Report on Form 8-K, the Company and Stonehill Capital Management LLC (“Stonehill”) entered into that certain Registration Rights Agreement (the “Registration Rights Agreement”), dated as of March 18, 2025 (the “Effective Date”). According to the Schedule 13D filed by Stonehill on February 21, 2025, Stonehill beneficially owns approximately 19.6% of the outstanding shares of Company common stock, par value $0.01 per share (“Common Stock”).

    Pursuant to the Registration Rights Agreement, the Company agreed to use its commercially reasonable efforts to (i) prepare and file, as soon as reasonably practicable after such time as when the Company has filed all reports and other materials required to be filed under the Exchange Act (as defined below) (“Current Reporting Status”), a “shelf” registration statement with the U.S. Securities and Exchange Commission (the “SEC”) that covers shares of Common Stock beneficially owned by Stonehill prior to or after the Effective Date, including shares of Common Stock issuable upon conversion of the 0.875% Convertible Senior Notes due 2027 of the Company beneficially owned by Stonehill, and (ii) cause such “shelf” registration statement to be declared effective by the SEC as soon as reasonably practicable thereafter. In addition, pursuant to the Registration Rights Agreement, the Company is required to use its commercially reasonable efforts to keep the Registration Statement continuously effective until the earlier to occur of (i) the date on which there are no longer any Registrable Securities (as defined in the Registration Rights Agreement) outstanding and (ii) the date on which Stonehill beneficially owns Registrable Securities representing 5% or less of the then-outstanding shares of Common Stock.

    Furthermore, if at any time following the Company’s obtaining Current Reporting Status, the Company proposes to register Common Stock for public sale under the U.S. Securities Act of 1933, as amended and the rules and regulations thereunder, or any similar successor statute (the “Securities Act”), the Company must provide notice to Stonehill of such intention, and Stonehill has the right to request that the Company use its commercially reasonable efforts to effect the registration under the Securities Act of all Registrable Securities which Stonehill has so requested to be registered, subject to certain customary exceptions.

    In addition, at any time following the Company’s obtaining Current Reporting Status, Stonehill may deliver a written request (the “Demand Request”) to the Company requesting that the Company effect the registration under the Securities Act of Registrable Securities and specifying the amount and intended method of disposition thereof (including, but not limited to, an underwritten public offering). Stonehill may deliver a Demand Request to the Company pursuant to the Registration Rights Agreement no more than once in any 12-month period. However, Stonehill is not permitted to deliver a Demand Request to the Company following the Company’s filing of a “shelf” registration that registers Registrable Securities for so long as such “shelf” registration statement remains effective.

    The Company and Stonehill also granted one another customary indemnification rights in connection with the Registration Rights Agreement.

    The foregoing description of the Registration Rights Agreement is qualified in its entirety by reference to the full text of the Registration Rights Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

    Confidentiality Agreement

    In connection with the appointment of Mr. Sacks to the Board, the Company, Mr. Sacks and Stonehill entered into that certain Confidentiality Agreement (the “Confidentiality Agreement”), dated as of the Effective Date. Among other things, the Confidentiality Agreement provides that if the Company holds an annual meeting of stockholders within one year of the Effective Date, the Company must, unless the Board determines that doing so would be inconsistent with its fiduciary duties under applicable law, (i) include Mr. Sacks in its slate of nominees for election as a director of the Company and (ii) list Mr. Sacks in the proxy statement and proxy card for such meeting and recommend that the Company’s stockholders vote in favor of Mr. Sacks.


    The foregoing description of the Confidentiality Agreement is qualified in its entirety by reference to the full text of the Confidentiality Agreement, a copy of which is attached hereto as Exhibit 10.2 and incorporated herein by reference.

     

    Item 5.02.

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On March 18, 2025, the Board (i) increased the size of the Board from six directors to seven directors and (ii) appointed Mr. Sacks to the Board, effective March 19, 2025. In addition, on March 18, 2025, the Board appointed Mr. Bruce Felt to the Board, effective upon, and to fill the vacancy created by, the resignation of Mr. P. Gregory Garrison from the Board on March 19, 2025. Each of Mr. Sacks and Mr. Felt was appointed in satisfaction of the Company’s obligations under the Cooperation Agreement, dated as of February 20, 2025 (the “Cooperation Agreement”), by and between the Company and Kent Lake PR LLC, a Puerto Rico limited liability company, and to hold office until the Company’s next annual meeting of stockholders. The material terms of the Cooperation Agreement are disclosed in the Company’s Current Report on Form 8-K filed with the SEC on February 20, 2025.

    The Board appointed Mr. Felt to serve as Chair of the Audit Committee of the Board, effective upon his appointment to the Board.

    Neither Mr. Sacks nor Mr. Felt is party to any other transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K. As non-employee directors, each of Messrs. Sacks and Felt will receive a pro rata portion of a $200,000 equity grant, a $60,000 annual cash retainer and a cash committee retainer of $2,500 for each committee on which Messrs. Sacks and Felt may serve in the aggregate.

     

    Item 7.01

    Regulation FD Disclosure.

    On March 18, 2025, the Company issued a press release announcing the appointments of Messrs. Sacks and Felt to serve as directors. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

    The information furnished pursuant to this Item shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    Number

      

    Exhibit Description

    10.1*    Registration Rights Agreement, dated as of March 18, 2025, by and between Veradigm Inc. and Stonehill Capital Management LLC
    10.2    Confidentiality Agreement, dated as of March 18, 2025, by and among Veradigm Inc., Jonathan Sacks and Stonehill Capital Management LLC
    99.1    Press release issued by Veradigm Inc. on March 18, 2025
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    *

    Exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted exhibits upon request by the SEC; provided that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any exhibits so furnished.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        VERADIGM INC.
    Date: March 18, 2025  
        By:  

    /s/ Eric Jacobson

        Name:   Eric Jacobson
        Title:  

    Senior Vice President, Deputy General Counsel and

    Corporate Secretary

    Get the next $MDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDRX

    DatePrice TargetRatingAnalyst
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    1/3/2024$11.00Equal Weight
    Barclays
    7/6/2023Buy → Hold
    Argus
    4/12/2023$13.00Equal-Weight
    Stephens
    2/1/2023$17.00 → $18.50Overweight → Neutral
    Piper Sandler
    12/7/2022$26.00Hold → Buy
    Argus
    11/9/2022$22.00 → $23.00Neutral → Buy
    Goldman
    11/4/2022$17.00Overweight
    Piper Sandler
    More analyst ratings

    $MDRX
    Financials

    Live finance-specific insights

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Veradigm to Release Financial Update March 18th and Host Investor Call March 19th

      Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a financial update after the close of regular stock market hours on March 18, 2025. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on March 19, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Tuesday, March 18, 2025. The announcement will also be available at the Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations we

      3/13/25 9:57:00 PM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review

      Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value. Review of Strategic Alternatives Throughout the review process, the Board, in collaboration with its financial and legal advisors, evaluated potential strategic opportunities, including a possible sale of the Company. Following the May 2024 public announcement of the process, the Company entered into confidenti

      1/30/25 4:02:00 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Sprinklr Set to Join S&P SmallCap 600

      NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector March 4, 2024 S&P SmallCap 600 Addition Sprinklr CXM Information Technology March 4, 2024 S&P SmallCap 600 Deletion Veradigm MDRX Hea

      2/28/24 5:50:00 PM ET
      $CXM
      $MDRX
      $SPGI
      Computer Software: Prepackaged Software
      Technology
      EDP Services
      Finance: Consumer Services

    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Veradigm downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously

      3/19/24 7:50:39 AM ET
      $MDRX
      EDP Services
      Technology
    • Barclays initiated coverage on Veradigm with a new price target

      Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00

      1/3/24 8:00:02 AM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm downgraded by Argus

      Argus downgraded Veradigm from Buy to Hold

      7/6/23 9:00:49 AM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Langan Thomas covered exercise/tax liability with 1,893 shares, decreasing direct ownership by 0.57% to 327,528 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      5/5/25 4:08:52 PM ET
      $MDRX
      EDP Services
      Technology
    • CEO Langan Thomas covered exercise/tax liability with 2,481 shares, decreasing direct ownership by 0.75% to 329,421 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      4/3/25 4:55:05 PM ET
      $MDRX
      EDP Services
      Technology
    • SVP & Chief HR Officer Hammond Lisa covered exercise/tax liability with 227 shares, decreasing direct ownership by 0.19% to 119,648 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      4/2/25 4:57:39 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Syracuse Orthopedic Specialists Selects Veradigm to Achieve Exceptional Financial Health and Operational Efficiency

      Veradigm to provide a comprehensive solution set to optimize revenue cycle and coding processes Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that Syracuse Orthopedic Specialists has selected elements from the Veradigm solution suite, Veradigm Revenue Cycle Services and Coding Services designed to support growth, improve cash flow and reduce costs. Syracuse Orthopedic Specialists, located near Syracuse, NY, provides total orthopedic care to the surrounding regions, and is currently utilizing Veradigm Revenue Analytics, Veradigm Practice Management and Veradigm Payerpath. Veradigm Revenue Cycle Services provides a robust suite of solu

      4/2/25 8:01:00 AM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services

    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Veradigm Inc.

      SC 13G - Veradigm Inc. (0001124804) (Subject)

      11/14/24 4:05:58 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

      SC 13G/A - Veradigm Inc. (0001124804) (Subject)

      11/14/24 1:11:13 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

      SC 13G/A - Veradigm Inc. (0001124804) (Subject)

      11/8/24 10:29:29 AM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4) (Amendment)

      4/A - Veradigm Inc. (0001124804) (Issuer)

      3/15/24 5:16:45 PM ET
      $MDRX
      EDP Services
      Technology
    • Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      3/4/24 9:50:46 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    SEC Filings

    See more
    • SEC Form 8-K filed by Veradigm Inc.

      8-K - Veradigm Inc. (0001124804) (Filer)

      4/22/25 4:23:28 PM ET
      $MDRX
      EDP Services
      Technology
    • SEC Form 8-K filed by Veradigm Inc.

      8-K - Veradigm Inc. (0001124804) (Filer)

      4/17/25 5:02:25 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form 8-K/A filed by Veradigm Inc.

      8-K/A - Veradigm Inc. (0001124804) (Filer)

      4/10/25 4:10:53 PM ET
      $MDRX
      EDP Services
      Technology